Shenyang Xingqi PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 2/4

Shenyang Xingqi PharmaceuticalLtd CEO'su E. Gao, Jul2022 tarihinde atandı, in görev süresi 2.33 yıldır. şirketin hisselerinin 1.19% doğrudan sahiptir ve bu hisselerin değeri CN¥ 171.28M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 13 yıl ve 3.8 yıldır.

Anahtar bilgiler

E. Gao

İcra Kurulu Başkanı

CN¥2.1m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	1.2%
Yönetim ortalama görev süresi	13yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

E. Gao (50 yo)

2.3yrs

Görev süresi

CN¥2,079,000

Tazminat

Ms. E. Gao serves as General Manager and MD at Shenyang Xingqi Pharmaceutical Co., Ltd. since July 18, 2022 and served as its Deputy General Manager until July 18, 2022. Ms. Gao serves as Director of Liaon...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
E. Gao	MD, GM & Non-Independent Director	2.3yrs	CN¥2.08m	1.19% CN¥ 171.3m
Shaoyao Zhang	Deputy Chairman	9.8yrs	CN¥2.08m	0.73% CN¥ 104.7m
Yanan Cheng	Deputy GM	13yrs	CN¥1.70m	0.21% CN¥ 30.6m
Chunhua Li	Director of the Administrative Management Department & Director	no data	CN¥1.43m	0.041% CN¥ 5.8m
Qiang Yang	Head of R&D Center	no data	CN¥1.32m	0.13% CN¥ 18.1m
NA NA	Head of the Accounting Department & Accounting Supervisor	no data	Veri yok	Veri yok
Fei Ji	Human Resources Specialist & Employee Representative Supervisor	no data	Veri yok	Veri yok

13.0yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim: 300573 'un yönetim ekibi deneyimli ve deneyimlidir ( 13 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
E. Gao	MD, GM & Non-Independent Director	13yrs	CN¥2.08m	1.19% CN¥ 171.3m
Shaoyao Zhang	Deputy Chairman	9.8yrs	CN¥2.08m	0.73% CN¥ 104.7m
Yanan Cheng	Deputy GM	6.8yrs	CN¥1.70m	0.21% CN¥ 30.6m
Chunhua Li	Director of the Administrative Management Department & Director	2.8yrs	CN¥1.43m	0.041% CN¥ 5.8m
Qiang Yang	Head of R&D Center	7.5yrs	CN¥1.32m	0.13% CN¥ 18.1m
Fei Ji	Human Resources Specialist & Employee Representative Supervisor	less than a year	Veri yok	Veri yok
Jidong Liu	Chairman of the Board	13yrs	CN¥6.00m	28.47% CN¥ 4.1b
Xiaobin Dai	Independent Director	3.8yrs	CN¥106.80k	Veri yok
Xiaoyu Qu	Chairman of the Supervisory Board	3.8yrs	Veri yok	Veri yok
Xianmei Xu	Independent Director	less than a year	Veri yok	Veri yok
Xiaoyan Kong	Independent Director	less than a year	Veri yok	Veri yok
Bing Li	Supervisor	less than a year	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300573 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Shenyang Xingqi PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024

Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections

High number of new directors

Less than half of directors are independent

Shenyang Xingqi Pharmaceutical Co., Ltd. Approves Directorate Elections

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.54 in 3Q 2023)

Investor sentiment deteriorates as stock falls 25%

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 19%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024

Second quarter 2024 earnings released: EPS: CN¥0.77 (vs CN¥0.39 in 2Q 2023)

High number of new directors

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dividend of CN¥3.00 announced

Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 1Q 2023)

Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: EPS: CN¥1.93 (vs CN¥1.72 in FY 2022)

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.66 in 3Q 2022)

New major risk - Share price stability

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023

Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023

High number of new directors

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023

Investor sentiment improves as stock rises 23%

Full year 2022 earnings released: EPS: CN¥2.41 (vs CN¥2.39 in FY 2021)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.93 (vs CN¥0.90 in 3Q 2021)

Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022

Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022

Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022

Second quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shenyang Xingqi Pharmaceutical Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented on A Shares, Payable on 20 May 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.40 in 1Q 2021)

Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for the Year 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.47 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Shenyang Xingqi Pharmaceutical Co., Ltd. Announces Final Cash Dividend for the Year 2020, Payable on 21 May 2021

Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥0.45 in FY 2019)

Shenyang Xingqi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥93.15

Shenyang Xingqi Pharmaceutical Co., Ltd. Approves Directorate Elections

New 90-day low: CN¥107

New 90-day low: CN¥124

Third quarter earnings released

New 90-day low: CN¥129

New 90-day low - CN¥136

Shenyang Xingqi Pharmaceutical Co.,Ltd announced that it expects to receive CNY 800 million in funding

Earnings released

Shenyang Xingqi Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi